Venöz tromboembolizme proteomik yaklaşımlar

Venöz tromboemboli (VTE) dünyada büyük bir halk sağlığı problemidir, ayrıca mortalite ve morbiditenin ana sebeplerindendir. VTE patogenezi multifaktöriyeldir ve gen değişimleri ile açıklanamayan epigenetik faktörler henüz tam olarak aydınlatılmış değildir. Proteomik teknolojileri proteinlerin global profillerini anlamamıza ve protein modifikasyonlarını açıklamamıza imkan sağlamaktadır. Böylelikle yeni biyobelirteçlerinin ve ilaç tedavilerinin belirlenmesinde yeni yaklaşımların geliştirilmesine de olanak sağlamaktadır. Bu derlemede tromboz tedavisinde yeni hedef moleküllerin bulunabilmesi açı-sından proteomik araştırmaların önemi tartışılmaktadır.

The proteomic approaches of venous thromboembolism

Venous thromboembolism is a major health problem all over the world and also a major cause of morbidity and mortality. The pathogenesis of this phenomenon is multifactorial and still there are unclear epigenetic factors that couldn’t explained with gene polymorphisms. Pro-teomic technologies enable to understanding of global profiling of proteins and the elucidation of protein modifications and thus also to provide approaches to the identification of new biomarkers and thrombolytic therapies. In this review, importance of proteomics researchs in terms of find out the new molecular markers for the treatment of thrombosis were discussed.

Kaynakça

1.

Available from: (http://www.who.int/chp/wright_centres/en/). 2.

Kurtoğlu M, Yanar H, Özkan Gürdal S. Venöz Tromboemboli Tanı, Tedavi Ve Profilaksi. Turkiye Klinikleri J Surg Med Sci 2006;2: 8-21. 3.

İşbir S. Venöz Tromboemboli Prolifaksisi: Güncel Kılavuz Bilgileri. Kronik venöz yetersizlik Sempozyum Dizisi No: 56;2007; 57-70. 4.

Güneş AM, Baytan B, Günay Ü. Çocukluk çağında kalıtsal tromboz. Güncel Pediatri 2004;2 : 91-7. 5.

Agnelli G, Becattini C. Treatment of DVT: how long is enough and how do you predict recurrence. J Thromb Thrombolysis 2008;25: 37-44. 6.

Lippi G, Franchini M, Montagnana M, Guidi GC. Genomics and Proteomics in Venous Thromboembolism: Building a Bridge toward a Rational Personalized Medicine Framework. Semin Thromb Hemost 2007;33: 759-70. 7.

Hung K Sun X, Ding H, Kalafatis M, Simioni P, Guo B, et al. A matrix-assisted laser desorption/ionization time-of-flight based method for screening the 1691G --> A mutation in the factor V gene. Blood Coagul Fibrinolysis 2002;13: 117-22. 8.

Humeny A, Bonk T, Berkholz A, Wildt L, Becker CM. Genotyping of thrombotic risk factors by MALDI-TOF mass spectrometry. Clin Biochem 2001;34: 531-6. 9.

Baktıroğlu S. Post-trombotik Sendrom. Turkiye Klinikleri J Gen Surg-Special Topics 2008;1: 78-82. 10.

Zhu T, Martinez I, Emmerich J. Venous thromboembolism: risk factors for recurrence. Arterioscler Thromb Vasc Biol 2009;29: 298-310. 11.

Palareti G. Current criteria to determine the duration of anticoagulant therapy. Recenti Prog Med 2007;98: 603-6. 12.

Oguzulgen IK, Demirtas S, Erkekol FO, Ekim N, Demir N, Numanoglu N, et al. The role of plasminogen activator inhibitor-1 polymorphism, factor-V-Leiden, and prothrombin-20210 mutations in pulmonary thromboembo-lism. Clin Appl Thromb Hemost 2009;15: 73-7. 13.

Sılan F, Zafer C. Faktör V Leiden mutasyonu. Düzce Tıp Dergisi 2004;1;33-6. 14.

Sarıman N. Homozigot faktör V Leiden (G1691 A) mutasyonuna bağlı tekrarlayan derin ven trombozu ve pulmoner emboli olgusu. Toraks Dergisi 2008;9: 80-3. 15.

Ferhanoğlu B. Trombofili. Tanıda İzlenecek Yol. Kanama ve Tromboza Eğilim Sempozyum Dizisi No: 36, 2003; 143-57. 16.

Juul K, Tybjaerg-Hansen A, Mortensen J, Lange P, Vestbo J, Nordestgaard BG, et al. Factor V leiden homozygosity, dyspnea, and reduced pulmonary function. Arch Intern Med 2005 26;165: 2032-6. 17.

Gelfi C, Viganò A, Ripamonti M, Wait R, Begum S, Biguzzi E, et al. A proteomic analysis of changes in prothrombin and plasma proteins associated with the G20210A mutation. Proteomics 2004;4: 2151-9. 18.

Bolaman Z, Ozkul A, Kiylioglu N, Kadikoylu G, Erturk A, Batun S, et al. Hereditary thrombophilic factors in stroke due to cerebral infarct. Am J Med Sci 2009;337: 11-3. 19.

Toth B, Vocke F, Rogenhofer N, Friese K, Thaler CJ, Lohse P, et al. Paternal thrombophilic gene mutations are not associated with recurrent miscarriage. Am J Reprod Immunol 2008;60: 325-32. 20.

Yildiz Z, Ulu A, Incesulu A, Ozkaptan Y, Akar N. The importance of thrombotic risk factors in the development of idiopathic sudden hearing loss. Clin Appl Thromb Hemost 2008;14: 356-9. 21.

Margaglione M, Brancaccio V, De Lucia D, Martinelli I, Ciampa A, Grandone E, et al. Inherited trombophilic risk factors and venous thrombophilic risk factors and venous thromboembolism. Chest 2000;118: 1405-11. 22.

Coppinger JA, Cagney G, Toomey S, Kislinger T, Belton O, McRedmond JP, et al. Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. Blood 2004;103: 2096- 104. 23.

Howes JM, Keen JN, Findlay JB, Carter AM. The application of proteomics technology to thrombosis research: the identification of potential therapeutic targets in cardiovascular disease. Diab Vasc Dis Res 2008;5: 205-12.

Kaynak Göster